20,119 Shares in NewAmsterdam Pharma Company N.V. $NAMS Bought by DNB Asset Management AS

DNB Asset Management AS purchased a new position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,119 shares of the company’s stock, valued at approximately $706,000.

A number of other hedge funds also recently modified their holdings of the stock. Navalign LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $46,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in NewAmsterdam Pharma in the fourth quarter valued at about $253,000. Swedbank AB bought a new position in NewAmsterdam Pharma in the fourth quarter valued at about $3,189,000. State of New Jersey Common Pension Fund D bought a new position in NewAmsterdam Pharma in the fourth quarter valued at about $539,000. Finally, Moody Aldrich Partners LLC bought a new position in NewAmsterdam Pharma in the fourth quarter valued at about $5,036,000. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Up 6.0%

Shares of NAMS stock opened at $35.75 on Thursday. The business’s 50-day moving average price is $32.59 and its 200-day moving average price is $34.26. NewAmsterdam Pharma Company N.V. has a 12 month low of $16.78 and a 12 month high of $42.21. The firm has a market capitalization of $4.18 billion, a price-to-earnings ratio of -19.97 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The firm had revenue of $3.04 million for the quarter. On average, sell-side analysts predict that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NAMS has been the topic of a number of recent analyst reports. Royal Bank Of Canada lifted their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Truist Financial initiated coverage on NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price on the stock. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and an average target price of $48.00.

Insider Buying and Selling

In related news, insider Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $30.30, for a total value of $3,165,350.10. Following the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at $2,099,850.60. The trade was a 60.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Louis G. Lange sold 44,619 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total value of $1,357,309.98. Following the completion of the transaction, the director directly owned 10,360 shares in the company, valued at approximately $315,151.20. This represents a 81.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,168,286 shares of company stock valued at $38,211,967 over the last ninety days. 12.74% of the stock is owned by company insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.